Emoxypine
A Russian antioxidant drug (a pyridine derivative related to vitamin B6) used for cerebrovascular and cardiovascular conditions. Nearly all clinical data is Russian-language; it is unfamiliar to Western regulators and sold as a research chemical.
01 Overview
Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine succinate; also known as mexidol) is a synthetic antioxidant and membrane-protective agent widely used in Russia and some post-Soviet states for ischaemic stroke, encephalopathy, anxiety and cardiovascular disease.
The supporting evidence is almost entirely from Russian-language trials that have not been widely replicated or scrutinised internationally. It is sold elsewhere as a research chemical and used as a nootropic for claimed anti-anxiety and neuroprotective effects.
02 Mechanism
Acts as a free-radical scavenger and membrane stabiliser, inhibiting lipid peroxidation and modulating GABA and other membrane-bound enzyme systems.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Therapeutic | 100–500 mg/day | IM | Injectable use in clinical settings in Russia. |
| Common | 125–375 mg/day | Oral | Russian dosing for succinate salt (mexidol); often divided. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Antioxidant neuroprotectionReduces lipid peroxidation in models; human translation not independently confirmed. | Preclinical | ||
| Anxiolytic effectReported in Russian trials for anxiety; limited external validation. | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Drowsiness / nauseaSleepiness, nausea or dry mouth reported. | Mild | Uncommon | Observational | |
| Unverified long-term safetyLimited independent scrutiny of long-term use. | Moderate | Unknown | Unconfirmed |